Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Summary

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

Timeline

Start

2025-10-30

Primary completion

2026-04-30

Completion

2026-06-30

Drugs

Indications